Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Bridgewater

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.
British Journal of Cancer|July 10, 2020
Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus positionChristopher M Jones, Ganesh Radhakrishna, Katharine Aitken, et al.
BMJ Open|October 26, 2022
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literatureMairéad G McNamara, John Bridgewater, Lipika Goyal, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2013
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)Gary Middleton, Sarah Brown, Catherine Lowe, et al.
British Journal of Cancer|November 3, 2020
Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic"Christopher M Jones, Ganesh Radhakrishna, Katharine Aitken, et al.
Hepatology (Baltimore, Md.)|June 14, 2024
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trialDo-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, et al.
The Lancet. Oncology|June 15, 2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialJulien Taieb, Josep Tabernero, Enrico Mini, et al.
BMC Cancer|May 4, 2017
Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L)Stuart A Taylor, Sue Mallett, Anne Miles, et al.
The Lancet. Oncology|April 11, 2014
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trialJohn Primrose, Stephen Falk, Meg Finch-Jones, et al.
Future Oncology (London, England)|July 18, 2020
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangementsTanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Journal of Hepatology|May 25, 2020
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancerMairéad Geraldine McNamara, Andre Lopes, Harpreet Wasan, et al.
British Journal of Cancer|July 10, 2020
Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus positionChristopher M Jones, Ganesh Radhakrishna, Katharine Aitken, et al.
BMJ Open|October 26, 2022
What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literatureMairéad G McNamara, John Bridgewater, Lipika Goyal, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2013
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)Gary Middleton, Sarah Brown, Catherine Lowe, et al.
British Journal of Cancer|November 3, 2020
Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic"Christopher M Jones, Ganesh Radhakrishna, Katharine Aitken, et al.
Hepatology (Baltimore, Md.)|June 14, 2024
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trialDo-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, et al.
The Lancet. Oncology|June 15, 2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialJulien Taieb, Josep Tabernero, Enrico Mini, et al.
BMC Cancer|May 4, 2017
Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L)Stuart A Taylor, Sue Mallett, Anne Miles, et al.
The Lancet. Oncology|April 11, 2014
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trialJohn Primrose, Stephen Falk, Meg Finch-Jones, et al.
Future Oncology (London, England)|July 18, 2020
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangementsTanios S Bekaii-Saab, Juan W Valle, Eric Van Cutsem, et al.
Pageof 13